10.5 USD
+0.09 (+0.86%)
Taking everything into account, TRHC scores 2 out of 10 in our fundamental rating. TRHC was compared to 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of TRHC have multiple concerns. TRHC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year TRHC has reported negative net income.
- TRHC had a negative operating cash flow in the past year.
1.2 Ratios
- TRHC has a Return On Assets (-26.82%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.82% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-23.32%
ROA(5y)-18.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of TRHC (23.61%) is worse than 83.72% of its industry peers.
- In the last couple of years the Gross Margin of TRHC has declined.
- The Profit Margin and Operating Margin are not available for TRHC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.61%
2. Health
2.1 Basic Checks
- TRHC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- TRHC has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for TRHC is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -0.66, we must say that TRHC is in the distress zone and has some risk of bankruptcy.
- TRHC's Altman-Z score of -0.66 is in line compared to the rest of the industry. TRHC outperforms 44.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.66 |
ROIC/WACCN/A
WACC8.36%
2.3 Liquidity
- A Current Ratio of 1.57 indicates that TRHC should not have too much problems paying its short term obligations.
- The Current ratio of TRHC (1.57) is worse than 60.47% of its industry peers.
- TRHC has a Quick Ratio of 1.47. This is a normal value and indicates that TRHC is financially healthy and should not expect problems in meeting its short term obligations.
- TRHC has a Quick ratio of 1.47. This is in the lower half of the industry: TRHC underperforms 60.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.47 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 50.00% over the past year.
- The Revenue has grown by 22.28% in the past year. This is a very strong growth!
- Measured over the past years, TRHC shows a quite strong growth in Revenue. The Revenue has been growing by 17.54% on average per year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112%
Revenue 1Y (TTM)22.28%
Revenue growth 3Y1.71%
Revenue growth 5Y17.54%
Sales Q2Q%24.02%
3.2 Future
- The Earnings Per Share is expected to grow by 34.23% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 17.28% on average over the next years. This is quite good.
EPS Next Y94.12%
EPS Next 2Y52.76%
EPS Next 3Y34.23%
EPS Next 5YN/A
Revenue Next Year21.88%
Revenue Next 2Y18.38%
Revenue Next 3Y17.28%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for TRHC. In the last year negative earnings were reported.
- With a Price/Forward Earnings ratio of 40.37, TRHC can be considered very expensive at the moment.
- 74.42% of the companies in the same industry are more expensive than TRHC, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of TRHC to the average of the S&P500 Index (24.26), we can say TRHC is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.37 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TRHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as TRHC's earnings are expected to grow with 34.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.76%
EPS Next 3Y34.23%
5. Dividend
5.1 Amount
- TRHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:TRHC (11/2/2023, 8:12:48 PM)
10.5
+0.09 (+0.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-07 2023-11-07/amc
Earnings (Next)03-04 2024-03-04/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners47.24%
Ins Owner Change0%
Market Cap284.02M
Revenue(TTM)338.12M
Net Income(TTM)-95.46M
Analysts48.89
Price Target10.71 (2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.51%
Min EPS beat(2)85.99%
Max EPS beat(2)125.03%
EPS beat(4)3
Avg EPS beat(4)27.01%
Min EPS beat(4)-127.59%
Max EPS beat(4)125.03%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.19%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)3.05%
Revenue beat(4)3
Avg Revenue beat(4)1.2%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)3.05%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)77.78%
EPS NY rev (1m)0%
EPS NY rev (3m)85.48%
Revenue NQ rev (1m)0.41%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.37 | ||
| P/S | 0.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.3
EYN/A
EPS(NY)0.26
Fwd EY2.48%
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS12.5
BVpS-2.89
TBVpS-9.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.82% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.61% | ||
| FCFM | N/A |
ROA(3y)-23.32%
ROA(5y)-18.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.61%
F-Score2
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 77.37% | ||
| Cap/Sales | 5.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.47 | ||
| Altman-Z | -0.66 |
F-Score2
WACC8.36%
ROIC/WACCN/A
Cap/Depr(3y)72.04%
Cap/Depr(5y)69.33%
Cap/Sales(3y)10.17%
Cap/Sales(5y)8.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112%
EPS Next Y94.12%
EPS Next 2Y52.76%
EPS Next 3Y34.23%
EPS Next 5YN/A
Revenue 1Y (TTM)22.28%
Revenue growth 3Y1.71%
Revenue growth 5Y17.54%
Sales Q2Q%24.02%
Revenue Next Year21.88%
Revenue Next 2Y18.38%
Revenue Next 3Y17.28%
Revenue Next 5YN/A
EBIT growth 1Y-16.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year137.28%
EBIT Next 3Y39.09%
EBIT Next 5YN/A
FCF growth 1Y0.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-320.17%
OCF growth 3YN/A
OCF growth 5Y-16.67%
TABULA RASA HEALTHCARE INC / TRHC FAQ
Can you provide the ChartMill fundamental rating for TABULA RASA HEALTHCARE INC?
ChartMill assigns a fundamental rating of 2 / 10 to TRHC.
Can you provide the valuation status for TABULA RASA HEALTHCARE INC?
ChartMill assigns a valuation rating of 2 / 10 to TABULA RASA HEALTHCARE INC (TRHC). This can be considered as Overvalued.
How profitable is TABULA RASA HEALTHCARE INC (TRHC) stock?
TABULA RASA HEALTHCARE INC (TRHC) has a profitability rating of 1 / 10.
How financially healthy is TABULA RASA HEALTHCARE INC?
The financial health rating of TABULA RASA HEALTHCARE INC (TRHC) is 1 / 10.
What is the earnings growth outlook for TABULA RASA HEALTHCARE INC?
The Earnings per Share (EPS) of TABULA RASA HEALTHCARE INC (TRHC) is expected to grow by 94.12% in the next year.